PEMBRO-K : Evaluation of Pembrolizumab Therapeutic Pharmacological Monitoring Benefit in NSCLC
Conditions: Non Small Cell Lung Cancer Sponsors: University Hospital, Angers Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Adapting and Testing a Novel Self-Compassion Intervention to Reduce Lung Cancer Stigma
Conditions: Lung Cancer Interventions: Behavioral: Mindful Self-Compassion for Lung Cancer (MSC-LC); Other: Enhanced standard of care with waitlist Sponsors: Loyola Marymount University; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD
Conditions: Non-Small Cell Lung Cancer Interventions: Other: None (Observational Study) Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
Diagnostic Accuracy Study for OWL-EVO1 as a Lung Cancer EVOC ® Probe (Evolution Phase 2)
Conditions: Lung Cancer Interventions: Diagnostic Test: OWL-EVO1 Sponsors: Owlstone Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Conditions: Non Small Cell Lung Cancer; EGFR Exon 20 Insertion Mutation Interventions: Drug: Furmonertinib Sponsors: Juan LI, MD Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
